MA40232A - Procédé de purification de la protéine de fusion tnfr:fc - Google Patents

Procédé de purification de la protéine de fusion tnfr:fc

Info

Publication number
MA40232A
MA40232A MA040232A MA40232A MA40232A MA 40232 A MA40232 A MA 40232A MA 040232 A MA040232 A MA 040232A MA 40232 A MA40232 A MA 40232A MA 40232 A MA40232 A MA 40232A
Authority
MA
Morocco
Prior art keywords
tnfr
fusion protein
purification
present
hcp
Prior art date
Application number
MA040232A
Other languages
English (en)
Inventor
Abir Banerjee
Chandranath Ganapathy
Ashok Mishra
Sorab Rustom Mody
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of MA40232A publication Critical patent/MA40232A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/12—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the preparation of the feed
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/20—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the conditioning of the sorbent material
    • B01D15/203—Equilibration or regeneration
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/30—Partition chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G, L chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3847—Multimodal interactions
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/42—Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
    • B01D15/424—Elution mode
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne la purification de la protéine de fusion tnfr:fc. L'invention concerne, plus précisément, un procédé de purification de la protéine de fusion tnfr:fc, caractérisé par une réduction du niveau des protéines des cellules hôtes (hcp). La présente invention concerne l'utilisation de la chromatographie en mode mixte et/ou de la chromatographie d'affinité pour produire une protéine de fusion tnfr:fc sensiblement exempte d'au moins l'une des enzymes de dégradation des protéines présentes dans les hcp.
MA040232A 2014-06-13 2015-06-13 Procédé de purification de la protéine de fusion tnfr:fc MA40232A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN1919MU2014 2014-06-13

Publications (1)

Publication Number Publication Date
MA40232A true MA40232A (fr) 2017-04-19

Family

ID=53524922

Family Applications (1)

Application Number Title Priority Date Filing Date
MA040232A MA40232A (fr) 2014-06-13 2015-06-13 Procédé de purification de la protéine de fusion tnfr:fc

Country Status (12)

Country Link
US (1) US10556942B2 (fr)
EP (1) EP3155009A1 (fr)
JP (1) JP6747985B2 (fr)
CN (1) CN106536565A (fr)
AU (1) AU2015273049B2 (fr)
BR (1) BR112016029157A8 (fr)
CA (1) CA2951766A1 (fr)
MA (1) MA40232A (fr)
MX (1) MX2016016318A (fr)
PH (1) PH12016502482A1 (fr)
RU (1) RU2698654C2 (fr)
WO (1) WO2015189832A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11566082B2 (en) 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
KR20170138426A (ko) * 2015-03-13 2017-12-15 삼성바이오에피스 주식회사 항-tnf-알파 폴리펩티드 조성물 및 그 용도
WO2017194593A1 (fr) 2016-05-11 2017-11-16 Ge Healthcare Bioprocess R&D Ab Procédé de nettoyage et/ou de désinfection d'une matrice de séparation
CN109311949B (zh) 2016-05-11 2022-09-16 思拓凡生物工艺研发有限公司 储存分离基质的方法
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
CN109071613A (zh) 2016-05-11 2018-12-21 通用电气医疗集团生物工艺研发股份公司 分离基质
US10889615B2 (en) 2016-05-11 2021-01-12 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
WO2019036626A1 (fr) * 2017-08-17 2019-02-21 Just Biotherapeutics, Inc. Procédé de purification de protéine glycosylée à partir de galectines et d'autres contaminants de cellules hôtes
IL272807B2 (en) * 2017-08-30 2024-07-01 Ares Trading Sa A method for cleaning proteins
US11952399B2 (en) * 2018-12-18 2024-04-09 Amgen Inc. Methods for purifying proteins
KR102286892B1 (ko) * 2019-07-08 2021-08-06 삼천당제약주식회사 안과용 단백질 제제의 정제방법
CN112876567A (zh) * 2019-11-29 2021-06-01 广东菲鹏制药股份有限公司 Fc融合蛋白及其纯化方法
WO2021181417A1 (fr) * 2020-03-11 2021-09-16 Dr. Reddy's Laboratories Limited Procédé de purification d'une protéine de fusion fc
CN113563469A (zh) * 2020-04-28 2021-10-29 江苏中新医药有限公司 高回收率纯化阿达木单抗的方法
WO2022234412A1 (fr) * 2021-05-03 2022-11-10 Lupin Limited Procédé de purification de protéines de fusion fc
EP4435107A1 (fr) * 2021-11-29 2024-09-25 Tosoh Corporation Procédé d'isolement d'anticorps

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2021284C1 (ru) * 1991-05-30 1994-10-15 Всесоюзный научно-исследовательский институт технологии кровезаменителей и гормональных препаратов Способ очистки клинических фракций декстрана
US7294481B1 (en) 1999-01-05 2007-11-13 Immunex Corporation Method for producing recombinant proteins
ES2311094T3 (es) 2002-02-27 2009-02-01 Immunex Corporation Composicion estabilizada de tnfr-fc que comprende arginina.
PT1601697E (pt) 2003-02-28 2007-09-04 Lonza Biologics Plc Purificação de anticorpos através de proteína a e cromatografia de troca iónica.
US8263750B2 (en) * 2006-03-16 2012-09-11 Amgen Inc. Method for purifying a protein using protein-A affinity chromatography using an intermediate wash step
JP2010501622A (ja) * 2006-08-28 2010-01-21 アレス トレーディング ソシエテ アノニム Ｆｃ−融合タンパク質の精製法
PL2061803T5 (pl) * 2006-08-28 2023-03-27 Ares Trading S.A. Proces oczyszczania białek zawierających fc
WO2009053360A1 (fr) * 2007-10-22 2009-04-30 Merck Serono S.A. Procédé de purification d'une protéine contenant fc
US20110129468A1 (en) * 2008-02-29 2011-06-02 Biogen Idec Ma Inc. Purified immunoglobulin fusion proteins and methods of their purification
CA2739352C (fr) * 2008-10-29 2021-07-13 Wyeth Llc Procedes de purification de molecules de liaison d'antigene monodomaines
SG182553A1 (en) * 2010-01-22 2012-08-30 Boehringer Ingelheim Int Chromatographic method for purifying fc-containing proteins
EP2723759A4 (fr) 2011-06-24 2015-01-28 Reddys Lab Ltd Dr Purification de protéine chimérique
JP6280499B2 (ja) * 2011-07-08 2018-02-14 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｆｃ融合タンパク質の精製方法
EP2753634B1 (fr) * 2011-08-17 2017-11-01 Ares Trading S.A. Procédé de préparation d'une forme active de la protéine de fusion tnfr-fc
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
ES2657377T3 (es) * 2012-09-11 2018-03-05 Coherus Biosciences, Inc. Etanercept plegado correctamente con alta pureza y excelente rendimiento
CN102911250B (zh) * 2012-09-29 2014-04-16 浙江海正药业股份有限公司 酸性重组蛋白药物的纯化方法
WO2014078627A1 (fr) * 2012-11-19 2014-05-22 Merck Sharp & Dohme Corp. Formulations liquides pour des protéines de fusion tnfr:fc
LT3395423T (lt) * 2013-03-14 2023-12-11 Amgen Inc. Pratekančių giminingumo gryninimo ligandų pašalinimas
US8946395B1 (en) * 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography

Also Published As

Publication number Publication date
BR112016029157A8 (pt) 2021-07-06
BR112016029157A2 (pt) 2017-08-22
RU2017100005A (ru) 2018-07-13
RU2698654C2 (ru) 2019-08-28
RU2017100005A3 (fr) 2019-02-28
JP6747985B2 (ja) 2020-08-26
US10556942B2 (en) 2020-02-11
CN106536565A (zh) 2017-03-22
EP3155009A1 (fr) 2017-04-19
CA2951766A1 (fr) 2015-12-17
WO2015189832A1 (fr) 2015-12-17
PH12016502482A1 (en) 2017-04-10
AU2015273049A1 (en) 2017-01-12
AU2015273049B2 (en) 2019-11-14
JP2017521389A (ja) 2017-08-03
MX2016016318A (es) 2017-06-12
US20170152298A1 (en) 2017-06-01

Similar Documents

Publication Publication Date Title
PH12016502482A1 (en) Process for the purification of tnfr:fc fusion protein
PH12018500711A1 (en) Anti-pd1 antibodies and methods of use
MX2023008559A (es) Proteínas de fusión fc heterodiméricas il15/il15ra.
PH12020550205A1 (en) IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE
MX2018010295A (es) Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos.
MX2016016886A (es) Anticuerpos anti-axl.
EP4299595A3 (fr) Compositions et procédés se rapportant à des constructions fc génétiquement modifiées
EP4335874A3 (fr) Anticorps anti-hla-g et leur utilisation
PH12018500707A1 (en) Anti-human cd19 antibodies with high affinity
NZ729451A (en) Antibodies, compositions, and uses
MX2022009875A (es) Anticuerpos y metodos de uso de anti-regiones de fragmentos cristalizables (fc) variantes.
MX2017010667A (es) Anticuerpos anti-proteína que contiene domino de inmunologlubina relacionado con el receptor de poliovirus (pvrig) y metodos de unso.
MX2017004691A (es) Bloqueo de cd73.
SG10201907582WA (en) Bicyclic heterocycles as fgfr4 inhibitors
AU2018333114A1 (en) New use for treatment of Clostridium difficile infections
MX2018009524A (es) Composiciones del polipeptido de fusion tnfr: fc exentas de arginina y metodos de uso.
WO2017015622A3 (fr) Protéines de liaison à gdf11 et leurs utilisations
SG10201908028SA (en) Cyclopropylamines as lsd1 inhibitors
WO2016061389A3 (fr) Anticorps anti-alpha-synucléine et leurs méthodes d'utilisation
IN2014DN08721A (fr)
AU2017317563A8 (en) Detergent compositions comprising xanthan lyase variants I
MX2018009266A (es) Conjugado de enzimas terapeuticas.
PH12020550927A1 (en) Therapeutic enzyme fusion protein having novel structure and use thereof
PH12020500054A1 (en) Novel therapeutic enzyme fusion protein and use thereof
MX2020003219A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.